Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Cash from Operations (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Cash from Operations data on record, last reported at 30555000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 43.67% year-over-year to 30555000.0; the TTM value through Sep 2025 reached 109521000.0, down 74.98%, while the annual FY2024 figure was 78180000.0, 112.09% down from the prior year.
  • Cash from Operations reached 30555000.0 in Q3 2025 per DNTH's latest filing, down from 23892000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 16375000.0 in Q3 2022 and bottomed at 30555000.0 in Q3 2025.
  • Average Cash from Operations over 4 years is 15079200.0, with a median of 14941000.0 recorded in 2024.
  • Peak YoY movement for Cash from Operations: surged 71.93% in 2023, then crashed 207.08% in 2024.
  • A 4-year view of Cash from Operations shows it stood at 8851000.0 in 2022, then plummeted by 33.93% to 11854000.0 in 2023, then tumbled by 131.52% to 27444000.0 in 2024, then decreased by 11.34% to 30555000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 30555000.0 in Q3 2025, 23892000.0 in Q2 2025, and 27630000.0 in Q1 2025.